The successful launch of its biosimilar Lucentis (ranibizumab) product last year provoked “a considerable amount of enthusiasm” from providers for competition to rival anti-VEGF blockbuster molecule, Eylea (aflibercept), Coherus BioSciences has explained in the wake of reversing its decision to compete in the planned aflibercept market.
Meanwhile, the company feels that the VEGF market “is one of the more interesting commercial opportunities,” having previously distanced itself in broader terms from